Earnings season in the biotech sector started on a positive note with Amgen (AMGN – Analyst Report) reporting better-than-expected first quarter 2015 results. Meanwhile, The Medicines Co. (MDCO – Analyst Report) received some good news with an FDA advisory panel backing its antiplatelet agent. However, companies like Athersys (ATHX – Snapshot Report) and Ampio suffered setbacks on the pipeline front.Recap […]
Biotech has been one hot sector again in 2015. Two key biotech exchange traded funds are up 20% or so on average year-to-date. 247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to 100% was predicted for four biotech and specialty pharma stocks.Before just chasing these higher, investors should understand […]
Biotech has been one hot sector again in 2015. Two key biotech exchange traded funds are up 20% or so on average year-to-date. 247 Wall St. could not help but notice four analyst calls this past week in which upside of 50% to 100% was predicted for four biotech and specialty pharma stocks.Before just chasing these higher, investors should understand […]
The Medicines Co. (MDCO – Analyst Report) was in the news for different reasons last week – while the company reported disappointing preliminary top-line results for the first quarter, later on the company received some good news with the FDA issuing positive briefing documents for Kengreal ahead of an advisory panel meeting. Other companies making it to the headlines over […]
Major updates in the biotech sector over the past four trading days were on the pipeline and regulatory front from companies like Alkermes (ALKS – Analyst Report) and Amgen (AMGN – Analyst Report) among others.Recap of the Week’s Most Important Stories1. Alkermes’ experimental schizophrenia treatment, ALKS 3831, fared well in a mid-stage study. Earlier this year, the company had said […]
View All3 Best-of-Breed Small Caps: Biotech Stocks to BuyNo one can deny the performance of biotech and biopharma stocks over the last six months as they have outperformed the entire market. The sector has done so well that it has brought back that dreaded word that everyone has feared in this sector since 2000: “bubble.”Source: ©iStock.com/AlexRathsHowever, it’s shortsighted to look at […]
Once again, acquisition news made it to the headlines with Horizon Pharma (HZNP – Snapshot Report) announcing that it will be acquiring Hyperion Therapeutics (HPTX – Snapshot Report). BioMarin has hit a 52-week high on acquisition rumors. Meanwhile, it’s been an eventful week on the pipeline and regulatory front as well with companies like Conatus (CNAT – Snapshot Report), Amgen […]
Posted by Jason Zweig on Mar 30, 2015 in Blog, Featured, Posts |Image credit: Genetically modified Amflora cells, BASF, flickr Creative CommonsBy Jason Zweig11:17 am ET Mar. 27, 2015In a research note out today, Credit Suisse analysts Ravi Mehrotra, Jason Kantor, Anuj Shah and Jeremiah Shepard write that biotechnology stocks are not in a bubble but “rather in a new […]
Wikimedia CommonsSee AlsoAviation tracking service: Germanwings co-pilot set autopilot to the lowest possible settingFed market gurus prep rate hike amid last-minute anxietiesWe just found out who the third American was on the crashed Germanwings flightNEW YORK (Reuters) – A 4 percent decline in biotechnology stocks on Wednesday sent the Nasdaq Composite Index to its largest one-day loss in nearly a […]
View All3 Explosive Biotech Stocks to Buy Once the Dust ClearsLeadership has its privileges … and its drawbacks. Right now, biotech stocks are realizing one of the drawbacks as this normally investor-loved sector is being taken behind the woodshed. The reason: Traders are closing positions to lock in profits during a seemingly risk-off moment for the markets.Source: ©iStock.com/ChepkoThe move is […]
